Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929370 · ClinicalTrials.gov registry record · Phase 1
A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.
A Phase 1 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00929370 is a Phase 1 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 34 participants.
The verdict
NCT00929370, a Phase 1 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to understand safety and tolerability of the drug GSK1018921 after 14 days of dosing in healthy volunteers and then in patient volunteers.
Interventions
- DRUG Glycine Transporter-1 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00929370
The ClinicalTrials.gov registry entry for NCT00929370 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glycine Transporter-1 inhibitor is the first listed.
NCT00929370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00929370 about?
NCT00929370 is a clinical study titled "A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.". The purpose of this study is to understand safety and tolerability of the drug GSK1018921 after 14 days of dosing in healthy volunteers and then in patient volunteers.
What is the current status of trial NCT00929370?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2008-07. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00929370?
The interventions under investigation include: Glycine Transporter-1 inhibitor (DRUG).
Who is sponsoring clinical trial NCT00929370?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.